Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.2% – What’s Next?

Bristol-Myers Squibb (NYSE:BMY)’s stock price shot up 0.2% during trading on Monday . The stock traded as high as $47.09 and last traded at $46.87. 2,132,546 shares were traded during trading, a decline of 84% from the average session volume of 13,189,523 shares. The stock had previously closed at $46.75.

Wall Street Analyst Weigh In

Several research firms have recently commented on BMY. UBS Group lowered their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Argus upgraded Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Cantor Fitzgerald restated a “neutral” rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Up 1.0%

The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm’s 50-day moving average is $53.05 and its two-hundred day moving average is $55.99. The stock has a market cap of $96.10 billion, a P/E ratio of -10.68, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb’s revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.40) EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.25%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 92.88%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the company’s stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.09% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $26,000. Global Wealth Strategies & Associates boosted its position in shares of Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares in the last quarter. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.